These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2975544)

  • 1. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview.
    Beck-Nielsen H; Hother-Nielsen O; Pedersen O
    Diabet Med; 1988 Oct; 5(7):613-20. PubMed ID: 2975544
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular effects of sulphonylureas: role of K(ATP) channels.
    Howes LG
    Diabetes Obes Metab; 2000 Apr; 2(2):67-73. PubMed ID: 11220526
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current concepts of the pancreatic and extrapancreatic mechanisms of the action of peroral hypoglycemic sulfonylurea preparations].
    Poltorak VV; Gladkikh AI
    Probl Endokrinol (Mosk); 1985; 31(2):76-85. PubMed ID: 2859589
    [No Abstract]   [Full Text] [Related]  

  • 4. Extrapancreatic effects of sulfonylurea drugs.
    Kaku K; Inoue Y; Kaneko T
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S105-8. PubMed ID: 8529502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Primary and secondary failure of sulphonylureas].
    Kanno H; Sakura H
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():719-23. PubMed ID: 12430308
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part I--"The pros".
    Waldhäusl W
    Horm Metab Res; 1996 Sep; 28(9):517-21. PubMed ID: 8911990
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pathophysiology of diabetes mellitus type 2 and the mechanism of action and indications for using hypoglycemic sulfonylurea derivatives].
    Tatoń J; Koliński P
    Pol Tyg Lek; 1985 May; 40(18):505-11. PubMed ID: 3892513
    [No Abstract]   [Full Text] [Related]  

  • 8. Does insulin preserve beta-cell function in type 2 diabetes?
    Heise T; Sawicki PT
    J Intern Med; 2002 Apr; 251(4):283-5. PubMed ID: 11952878
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanism of insulin secretion and its modulation by sulfonylureas.
    Panten U
    Contrib Nephrol; 1989; 73():16-21; discussion 22-3. PubMed ID: 2689091
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man.
    Pfeifer MA; Halter JB; Judzewitsch RG; Beard JC; Best JD; Ward WK; Porte D
    Diabetes Care; 1984; 7 Suppl 1():25-34. PubMed ID: 6376026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do sulfonylureas influence hepatic insulin clearance?
    Groop LC; Groop PH; Stenman S; Saloranta C; Tötterman KJ; Fyhrquist F; Melander A
    Diabetes Care; 1988 Sep; 11(8):689-90. PubMed ID: 3065007
    [No Abstract]   [Full Text] [Related]  

  • 12. Different amounts of insulin secretion following an equal total decrease of blood glucose as an indication of possible extrapancreatic activities of different sulfonylurea drugs.
    Beyer J; Haupt E; Cordes U; Kutschera J; Schöffling K
    Horm Metab Res; 1973 Jan; 5(1):9-13. PubMed ID: 4196346
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin release form isolated, human islets after acute or prolonged exposure to glimepiride.
    Del Guerra S; Parentini C; Bracci C; Lupi R; Marselli L; Aragona M; Navalesi R; Marchetti P
    Acta Diabetol; 2000; 37(3):139-41. PubMed ID: 11277315
    [No Abstract]   [Full Text] [Related]  

  • 15. A 12-h intravenous insulin infusion restores the beta-cell response torpidity to sulfonylureas in patients affected by type 2 diabetes.
    Sinagra D; Greco D; Amato MC; D'Acquisto G; Galluzzo A
    Diabetes Care; 2000 Dec; 23(12):1857-8. PubMed ID: 11128371
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical efficacy of glimepiride].
    Kaneko T; Sakamoto N
    Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of transglutaminase by hypoglycaemic sulphonylureas in pancreatic islets and its possible relevance to insulin release.
    Gomis R; Mathias PC; Lebrun P; Malaisse-Lagae F; Sener A; Malaisse WJ
    Res Commun Chem Pathol Pharmacol; 1984 Dec; 46(3):331-49. PubMed ID: 6151221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular mechanism of action of sulfonylureas].
    Ammon HP
    Dtsch Med Wochenschr; 1988 May; 113(21):864-70. PubMed ID: 3286184
    [No Abstract]   [Full Text] [Related]  

  • 19. Cellular loci of sulfonylurea actions.
    Lebovitz HE
    Diabetes Care; 1984; 7 Suppl 1():67-71. PubMed ID: 6376031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in studies on antidiabetic agents].
    Tang L; Yang YS; Ji RY
    Yao Xue Xue Bao; 2001 Sep; 36(9):711-5. PubMed ID: 12580115
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.